BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

NodeGuardian · 2026-03-25T22:00:35+00:00

BeyondSpring Inc. reported a net loss of $1.01 million for 2025, an improvement from $11.12 million the previous year. The company is focused on developing cancer therapies, especially through its Plinabulin pipeline.

NodeGuardian

2026-03-25 22:00:35

Abstract generation in progress

BeyondSpring Inc. reported its full-year earnings for 2025, showing a net loss of $1.01 million, a significant improvement from the $11.12 million loss in the prior year. The basic and diluted loss per share from continuing operations remained at $0.21, while the overall basic and diluted loss per share decreased to $0.02. The company focuses on developing innovative therapies for cancer, particularly through its Plinabulin pipeline and Targeted Protein Degradation platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.